What Buscopan Plus Treats: Main Uses and Benefits

The primary therapeutic use of this medicine is to help manage paroxysmal and spastic pain in various bodily systems. The therapeutic domain includes situations involving symptomatic discomfort within the digestive, biliary, urinary, and female genital systems (e.g., menstrual cramps). It is applied across domains where additional symptomatic support is needed to address discomfort caused by muscle spasms.

The formulation is often used during phases of increased distress or discomfort when short-term symptomatic assistance is needed. This use helps address symptom clusters that may become intense or disruptive, assisting with maintaining functional stability.

“This medicine is relevant for easing pain associated with functional disorders in the biliary, urinary, and female genital organs, such as menstrual cramps.”

---

Quick Fact Block

Quick Fact: Support for Symptoms of Physical Discomfort

The medicine generally helps ease symptoms related to heightened physiological activity, supporting patients during difficult or recurrent episodes of discomfort.

Regulatory References

1. Indonesia BPOM Company Core Data Sheet

Buscopan Plus is a combination medicine containing hyoscine butylbromide and paracetamol (acetaminophen). Regulatory information strictly defines which populations are eligible to use it.

Contraindicated Populations (Must Not Use)

Use of Buscopan Plus is contraindicated in patients with:

• Hypersensitivity (allergy) to hyoscine butylbromide, paracetamol, or any component.
• Gastrointestinal obstructions (e.g., mechanical stenosis, paralytic or obstructive ileus, megacolon).
• Myasthenia gravis (a muscle weakness disorder).
• Severe hepatocellular insufficiency (severe liver failure).
• Rare hereditary conditions such as fructose intolerance, due to the excipient content.

Restricted or Not Recommended Use

• Age: It is not suitable for children under 10 years of age.
• Pregnancy and Lactation: Use is not recommended during both pregnancy and breast-feeding.
• Hepatic/Renal Impairment: Patients with severe renal insufficiency, mild to moderate liver insufficiency (Child-Pugh A/B), Gilbert's syndrome, or low glutathione reserves should only use the medicine under strict medical supervision and potentially with dose adjustment.
• Duration: The medicine should not be taken for more than 3 days without consulting a physician. Caution is also advised for patients with certain heart conditions or susceptibility to complications like narrow-angle glaucoma.

The interaction profile for Buscopan Plus is defined by the combined risks of its two active components, Acetaminophen and Hyoscine Butylbromide. The official regulatory documents structure the constraints based on these components.

Mandatory Restrictions and High-Risk Combinations The most critical regulatory constraint involves preventing overexposure. Co-administration is strictly restricted with any other medicine containing Acetaminophen (Paracetamol) to prevent cumulative overdose. Alcohol consumption must be avoided as it is officially documented to increase the risk of hepatotoxicity from the analgesic component.

Pharmacodynamic Interactions The spasmolytic component, Hyoscine Butylbromide, can lead to pharmacodynamic potentiation. The anticholinergic effects of other medicines, such as tricyclic antidepressants and certain antihistamines, may be intensified. Furthermore, Beta-adrenergic agents carry an increased risk of enhanced tachycardic effects. Dopamine Antagonists (e.g., Metoclopramide) may diminish beneficial effects on gastrointestinal motility.

Exposure-Altering and Other Interactions Interactions affecting drug exposure include those that reduce clearance, such as Probenecid, which reduces the excretion of Acetaminophen. This constraint may require adjustment of the Acetaminophen dose. Conversely, Colestyramine reduces absorption. Other interactions officially noted include an increased bleeding risk with Warfarin and an increased likelihood of neutropenia when co-administered with Zidovudine. Acetaminophen may also interfere with laboratory tests for uric acid and blood sugar levels.

The pharmacological activity of Buscopan Plus relies on a dual mechanistic strategy targeting autonomic hyperactivity and nociceptive signaling, which are executed by two distinct components.

Peripheral Anticholinergic Mechanism: Spasmolysis

This domain centers on Hyoscine Butylbromide acting as a competitive antagonist at peripheral muscarinic acetylcholine receptors on the smooth muscle of the gastrointestinal and genitourinary tracts. By blocking the signal of the parasympathetic autonomic pathway, this mechanism suppresses the involuntary contraction of visceral muscle, resulting in smooth muscle relaxation (spasmolysis).

Central Analgesic Mechanism: Nociceptive Signal Dampening

The second domain involves Acetaminophen modulating nociceptive signaling predominantly within the Central Nervous System (CNS) by inhibiting central COX enzymes and engaging descending pain pathways via its AM404 metabolite. This action elevates the central pain threshold, thereby altering the transmission of nociceptive signals.

How to Use Buscopan Plus: Official Administration Guidelines

This section details the authorized administrative pattern for the Buscopan Plus combination medicine and is not a substitute for professional medical advice.

---

Administration Principles

The standard method of using this medicine is limited to the oral route of administration via the film-coated tablet. The dosage is defined for short-term, intermittent use, generally not to exceed three days unless advised otherwise by a physician.

---

Dosing and Scheduling

Category	Official Use Principle
Standard Dosing (Adults)	The typical single dose is 1 to 2 tablets.
Frequency	Doses may be taken up to 3 times daily (TID).
Daily Maximum	The maximum daily limit is either 4 or 6 tablets, depending on regional guidelines.
Dosing Interval	A minimum interval of at least 8 hours between administrations is specified in certain regimens.

---

Procedural and Population Rules

Tablets must be swallowed whole and unchewed with an adequate amount of liquid, as the tablet's score is not intended for division. Use of the product is restricted to individuals 10 years of age and older. For patients with impaired liver or kidney function, a dose reduction or a prolongation of the time interval between doses is officially required to be determined under medical supervision. The presence of sucrose in the tablet imposes a use constraint for individuals with certain hereditary sugar intolerances.

Research evidence / Overview of studies for Buscopan Plus

This overview summarizes the official clinical research and regulatory evidence available for the fixed combination of Hyoscine Butylbromide and Acetaminophen/Paracetamol, focusing only on the types of studies conducted, the populations they examined, and the overall research landscape.

---

Evidence for Recurrent Spasmodic Abdominal Pain

The primary research for this fixed-dose combination was studied for use in populations experiencing symptoms of recurrent abdominal discomfort and conditions characterized by fluctuating manifestations. These investigations included randomized controlled trials (RCTs) where researchers observed the combination’s performance against both a placebo and its single active components.

The studies included adults and adolescents (generally 12 years and older). Main study outcomes examined were patient-reported outcomes describing perceived discomfort, specifically quantifying changes in pain intensity over the study period. Long-term outcomes are not fully established, and durability of observed symptomatic patterns beyond the typical three-to-four-week study duration are not broadly characterized.

---

Evidence for Spastic Pain Associated with Menstrual Cramps

Research examined the use of the medicine for outcomes related to physical discomfort experienced during menstrual cramps (dysmenorrhea). Studies utilized designs such as double-blind crossover trials to evaluate the acute symptom patterns in women.

The trials monitored several outcomes describing episodic or acute changes, including measuring changes in pain and cramp intensity, alongside evaluating outcomes reflecting daily functioning or activity level. Data for continued use over many menstrual cycles remain insufficient, and comparative evidence is lacking against the full range of alternative non-prescription options.

---

Research in Specific Groups and Populations

The primary research examining this fixed combination was evaluated in generally healthy adults and adolescents with the specific symptoms being studied. Results apply only to the populations studied. Data for certain groups remain insufficient; for instance, there is limited clinical evidence from dedicated trials involving older adults or those with certain significant underlying health conditions, and data for certain groups remain insufficient (e.g., in pregnancy-related contexts).

Key Studies & References

1. Assesment Reports No. 01763522700 - Buscopan Plus (Fixed Combination Regulatory Monograph)
2. Efficacy and safety of a fixed combination of N-butylscopolamine and paracetamol in patients with recurrent abdominal pain: a randomized, placebo-controlled, multicentre trial.
3. Acetaminophen (Oral Route) - MedlinePlus Drug Information

Common questions about Buscopan Plus (FAQ)

---

Q: Can I take Buscopan Plus for chronic abdominal pain?

A: Buscopan Plus is typically used for the symptomatic treatment of mild to moderate pain associated with muscle spasms of the gastrointestinal tract. It is generally intended for short-term, acute episodes. For chronic or long-lasting pain, it is important to consult a healthcare provider for a thorough diagnosis and management plan, as the medication may not address the underlying cause.

---

Q: How quickly does Buscopan Plus begin to work?

A: The onset of action for the components in Buscopan Plus can vary among individuals. Generally, relief from spasms and associated pain may be noticed relatively quickly after ingestion. If symptoms persist or worsen, consult a doctor or pharmacist.

---

Q: Is Buscopan Plus safe to use during pregnancy or while breastfeeding?

A: It is recommended that individuals who are pregnant, planning to become pregnant, or breastfeeding discuss the use of any medication, including Buscopan Plus, with their healthcare provider. Official product information often advises against its use in these populations unless considered necessary by a physician, based on a risk-benefit assessment.

---

Q: Does Buscopan Plus interact with other pain relievers?

A: The active ingredients in Buscopan Plus may interact with certain other medications, including some types of other pain relievers (like certain non-steroidal anti-inflammatory drugs or NSAIDs). It is important to disclose all current medications, including over-the-counter products, to a pharmacist or doctor to check for potential interactions before starting treatment.

Buscopan Plus tablets must be stored at temperatures not exceeding 30 C to maintain product integrity, as directed by official regulatory labeling. Storage conditions require that the medicine be protected from light, heat, and moisture. It should be kept in a cool, dry place and remain in its original packaging until the time of use.

Official Storage Requirements

Condition	Requirement (as stated in regulatory documents)
Temperature	Store below 30 C
Protection	Protected from light, heat, and moisture
Safety	Keep out of the sight and reach of children
Stability	Do not use after the expiry date

For disposal, unused or expired tablets must not be thrown away with household waste or wastewater. The officially recommended method is to return the medicine to a pharmacy for safe disposal or use an authorized drug take-back location. If a take-back option is unavailable, the tablets may be mixed with an undesirable substance (like dirt or cat litter) in a sealed container and placed in the trash, as per general regulatory guidelines.